Sign in
Taking people in United StatesPhase 2

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

Key facts

Who runs it
GlaxoSmithKline
Where
Arlington, Atlanta, Austin, Brandon, Chandler, Chapel Hill, Cleveland, Coronado, Dallas, Detroit, Fort Worth, Georgetown, Hermitage, Indianapolis, Lancaster, Las Vegas, Los Angeles, Marrero, McAllen, Miami, Miami Lakes, New York, Pasadena, Philadelphia, Phoenix, Richmond, Sacramento, San Antonio, Topeka, and Tucson, United StatesSee the 30 sitesAlso in 18 other countries, 88 sites
Status
Recruiting
Phase
Phase 2
People taking part
350 people, planned
Started
27 Sept 2024
Expected to end
2 Mar 2029
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • GSK4532990
  • Placebo
Record updated
13 November 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Participant must be 18 to 70 years of age inclusive, at the time of screening. (Participants in South Korea must be greater than or equal to [>=] 19 years of age and participants in Japan must be >= 20 years of age.)
  • Capable of giving signed informed consent prior to the performance of any study-specific procedures
  • Able and willing to comply with all study assessments and adhere to the protocol schedule of activities
  • In the opinion of the investigator, there is a history of alcohol consumption compatible with either ALD or Met ALD
  • A female participant is eligible to participate after meeting additional pre-defined criteria
  • Participants must meet predefined stable use requirements of concomitant medications based on study criteria
  • Participant has advanced chronic liver disease

Who cannot take part

  • Prior organ transplant (except for corneal transplants)
  • Prior Transjugular Intrahepatic Portosystemic Shunt (TIPSS) insertion
  • Any acute cardiovascular event including myocardial infarction, unstable angina, symptomatic heart failure, or cerebrovascular accident in the 6 months prior to screening
  • Meeting any definition of organ system failure as defined by the North American Consortium for Study of End-stage Liver Disease (NACSELD)
  • Current malignancy (except for basal cell carcinoma or uterine carcinoma-in-situ) at screening. Participants under evaluation for possible malignancy at screening are not eligible
  • Chronic or acute, including partial, known portal vein thrombosis
  • Poorly controlled hypertension
  • Clinical suspicion of a bleeding episode during the screening period related to portal hypertension and/or low blood fibrinogen level
  • Exceeding pre-defined biochemical parameters for ALT, AST, ALP, Platelets, INR, Albumin, eGFR, UACR or HbA1c. Other primary causes of liver disease based on study criteria
  • Clinical suspicion of rhabdomyolysis during the screening period

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

Also in 18 other countries, 88 sites

  • Arlington, TexasHospital not named in the registryContact: Reem Ghalib (principal investigator)Taking people
  • Atlanta, GeorgiaHospital not named in the registryContact: Lance Stein (principal investigator)Taking people
  • Austin, TexasHospital not named in the registryContact: Rohit Puskoor (principal investigator)Taking people
  • Brandon, FloridaHospital not named in the registryContact: Patrick Weston (principal investigator)Taking people
  • Chandler, ArizonaHospital not named in the registryContact: Anita Kohli (principal investigator)Taking people
  • Chapel Hill, North CarolinaHospital not named in the registryContact: Hersh Shroff (principal investigator)Taking people
  • Cleveland, OhioHospital not named in the registryContact: Srinivasan Dasarathy (principal investigator)Taking people
  • Coronado, CaliforniaHospital not named in the registryContact: Tarek Hassanein (principal investigator)Taking people
  • Dallas, TexasHospital not named in the registryContact: Mangesh Pagadala (principal investigator)Taking people
  • Detroit, MichiganHospital not named in the registryContact: Syed-Mohammed Jafri (principal investigator)Taking people
  • Fort Worth, TexasHospital not named in the registryContact: Thomas Cotter (principal investigator)Taking people
  • Georgetown, TexasHospital not named in the registryContact: Rohit Puskoor (principal investigator)Taking people
  • Hermitage, TennesseeHospital not named in the registryContact: Donald Lazas Jr (principal investigator)Taking people
  • Indianapolis, IndianaHospital not named in the registryContact: Raj Vuppalanchi (principal investigator)Taking people
  • Lancaster, PennsylvaniaHospital not named in the registryContact: Jatinder Pruthi (principal investigator)Taking people
  • Las Vegas, NevadaHospital not named in the registryContact: Elliot Shin (principal investigator)Taking people
  • Los Angeles, CaliforniaHospital not named in the registryContact: Norah Terrault (principal investigator)Taking people
  • Marrero, LouisianaHospital not named in the registryContact: Gary Reiss (principal investigator)Taking people
  • McAllen, TexasHospital not named in the registryNo longer taking part
  • Miami, FloridaHospital not named in the registryContact: Barbara Moscoso (principal investigator)Taking people
  • Miami Lakes, FloridaHospital not named in the registryContact: William Sanchez (principal investigator)Taking people
  • New YorkHospital not named in the registryContact: Frances Lee (principal investigator)Taking people
  • Pasadena, CaliforniaHospital not named in the registryContact: Edward Mena (principal investigator)Taking people
  • Philadelphia, PennsylvaniaHospital not named in the registryContact: K. Rajender Reddy (principal investigator)Taking people
  • Phoenix, ArizonaHospital not named in the registryContact: Moises Nevah Rubin (principal investigator)Taking people
  • Richmond, VirginiaHospital not named in the registryContact: Amon Asgharpour (principal investigator)Taking people
  • Sacramento, CaliforniaHospital not named in the registryContact: Vikrant Rachakonda (principal investigator)Taking people
  • San Antonio, TexasHospital not named in the registryContact: Eric Lawitz (principal investigator)Taking people
  • Topeka, KansasHospital not named in the registryContact: Shekhar Challa (principal investigator)Taking people
  • Tucson, ArizonaHospital not named in the registryContact: Aimee Bachelier (principal investigator)Taking people

About the trial

What the trial wants to find out

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

The 5 groups in the trial

  • GSK4532990 Dose 1Treatment being tested

    Treatment: GSK4532990

  • GSK4532990 Dose 2Treatment being tested

    Treatment: GSK4532990

  • GSK4532990 Dose 3Treatment being tested

    Treatment: GSK4532990

  • GSK4532990 Dose 4Treatment being tested

    Treatment: GSK4532990

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)
Criteria questions
Built from NCT06613698, who can take part
Record updated
13 November 2026